WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE ...

Little is known about what causes ovarian cancer, and there is no way to detect it early yet. About 75% of the time when ...

The shares of this leading pharmaceutical company are in focus after the company secured the USFDA's approval for its key ...

Obesity, a growing global epidemic, is identified as a significant, modifiable risk factor for ovarian cancer, a deadly ...

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy ...

In a pilot programme involving 840 patients with various cancers, the test successfully categorised individuals as either ...

Clinical application: Treatment in a mouse model with milciclib in combination with mirvetuximab significantly reduced tumor ...

Chris Evert says she now considers every day "precious" after twice battling cancer and admits that getting to "the lowest ...

Ovarian cancer in particular ... doesn't have great survival,” said one researcher. “Anything we can do to better understand ...

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ...

The relationship between hormone therapy (oestrogen with or without progestogen) and breast cancer risk has been widely ...